CY1125793T1 - Εξουδετερωτικα μορια δεσμευσης κατα της γριπης και χρησεις αυτων - Google Patents

Εξουδετερωτικα μορια δεσμευσης κατα της γριπης και χρησεις αυτων

Info

Publication number
CY1125793T1
CY1125793T1 CY20211100923T CY211100923T CY1125793T1 CY 1125793 T1 CY1125793 T1 CY 1125793T1 CY 20211100923 T CY20211100923 T CY 20211100923T CY 211100923 T CY211100923 T CY 211100923T CY 1125793 T1 CY1125793 T1 CY 1125793T1
Authority
CY
Cyprus
Prior art keywords
influenza
binding molecules
neuterial
binding
molecules
Prior art date
Application number
CY20211100923T
Other languages
English (en)
Inventor
Nicole KALLEWAARD-LELAY
Qing Zhu
Godfrey Jonah RAINEY
Cuihua Gao
Srinath Kasturirangan
Changshou Gao
Original Assignee
Medimmune, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune, Llc filed Critical Medimmune, Llc
Publication of CY1125793T1 publication Critical patent/CY1125793T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Αποκαλύπτονται μόρια δέσμευσης, που περιλαμβάνουν διειδικά μόρια τα οποία περιλαμβάνουν τουλάχιστον δυο επικράτειες δέσμευσης κατά της γρίπης, συμπεριλαμβανομένων μορίων δέσμευσης που έχουν μια πρώτη επικράτεια δέσμευσης που δεσμεύει ειδικώς ιό γρίπης Α και μια δεύτερη επικράτεια δέσμευσης που δεσμεύει ειδικώς ιό γρίπης Β.
CY20211100923T 2015-06-01 2021-10-21 Εξουδετερωτικα μορια δεσμευσης κατα της γριπης και χρησεις αυτων CY1125793T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562169272P 2015-06-01 2015-06-01
PCT/US2016/035026 WO2016196470A1 (en) 2015-06-01 2016-05-31 Neutralizing anti-influenza binding molecules and uses thereof

Publications (1)

Publication Number Publication Date
CY1125793T1 true CY1125793T1 (el) 2024-02-16

Family

ID=56118059

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100923T CY1125793T1 (el) 2015-06-01 2021-10-21 Εξουδετερωτικα μορια δεσμευσης κατα της γριπης και χρησεις αυτων

Country Status (21)

Country Link
US (4) US10442854B2 (el)
EP (2) EP3960761A1 (el)
JP (3) JP6867306B2 (el)
CN (2) CN107667114B (el)
AU (2) AU2016271323B2 (el)
BR (1) BR112017025496A2 (el)
CA (1) CA2987816C (el)
CY (1) CY1125793T1 (el)
DK (1) DK3303384T3 (el)
ES (1) ES2894777T3 (el)
HK (2) HK1250725A1 (el)
HR (1) HRP20211510T1 (el)
HU (1) HUE056407T2 (el)
LT (1) LT3303384T (el)
MX (2) MX2017015189A (el)
PL (1) PL3303384T3 (el)
PT (1) PT3303384T (el)
RS (1) RS62446B1 (el)
RU (1) RU2721706C2 (el)
SI (1) SI3303384T1 (el)
WO (1) WO2016196470A1 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2683498C2 (ru) 2013-10-02 2019-03-28 МЕДИММЬЮН, ЭлЭлСи Нейтрализующие антитела к вирусу гриппа а и пути их применения
RU2739952C2 (ru) 2014-07-15 2020-12-30 МЕДИММЬЮН, ЭлЭлСи Нейтрализующие антитела к вирусу гриппа b и пути их применения
SI3303384T1 (sl) * 2015-06-01 2021-11-30 Medimmune Llc Nevtralizirajoče vezavne molekule proti-influenci in njihova uporaba
EP3402513A4 (en) 2016-01-13 2019-10-23 Medlmmune, LLC METHOD OF TREATING A FLU
EA202091563A1 (ru) 2018-01-26 2020-10-08 Регенерон Фармасьютикалз, Инк. Человеческие антитела к гемагглютинину вируса гриппа
CN114761428A (zh) * 2019-10-28 2022-07-15 瑞泽恩制药公司 抗血凝素抗体及其使用方法
CN113121680B (zh) * 2021-04-12 2022-03-29 华南农业大学 一种抗h5亚型禽流感纳米抗体蛋白及其编码基因与应用
WO2023196658A2 (en) * 2022-04-08 2023-10-12 Cz Biohub Sf, Llc Antibody compositions and optimization methods
CN116874606B (zh) * 2023-09-08 2023-11-24 益科思特(北京)医药科技发展有限公司 一种靶向trop2和cd3的双特异性抗体及其制备方法与应用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
DE69621940T2 (de) 1995-08-18 2003-01-16 Morphosys Ag Protein-/(poly)peptidbibliotheken
SE9504046D0 (sv) 1995-11-14 1995-11-14 Pharmacia Ab Method of determining affinity and kinetic properties
CA2254108C (en) 1996-05-23 2008-07-22 Unilever Plc Improvements in or relating to specific binding assays
WO1998057993A1 (en) 1997-06-19 1998-12-23 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP1135498B1 (en) 1998-11-18 2008-01-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
AU3328900A (en) 1999-03-31 2000-10-23 Otsuka Pharmaceutical Co., Ltd. Influenza virus hemagglutinin-binding peptides
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
WO2001062907A1 (en) 2000-02-22 2001-08-30 Medical & Biological Laboratories Co., Ltd. Antibody library
CA2412701A1 (en) 2000-06-28 2002-01-03 Glycofi, Inc. Methods for producing modified glycoproteins
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
JP2005530845A (ja) 2002-06-21 2005-10-13 アイデック ファーマシューティカルズ コーポレイション 抗体を濃縮するための緩衝化処方物およびその使用方法
AU2003251809A1 (en) 2002-07-11 2004-02-02 The General Hospital Corporation Polynucleotide and polypeptide fat metabolism regulators and uses thereof
CN1934133B (zh) 2003-07-23 2011-12-14 富士瑞必欧株式会社 抗a型流感病毒单克隆抗体及使用该抗体的免疫测定器具
WO2005014038A1 (ja) 2003-08-11 2005-02-17 The Research Foundation For Microbial Diseases Of Osaka University 粘膜免疫誘導アジュバントを含む新規ワクチン
CA3052445C (en) 2004-07-10 2023-08-22 Kerry S. Campbell Genetically modified human natural killer cell lines
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
EP2532679B1 (en) 2005-10-21 2017-04-12 Novartis AG Human antibodies against il13 and therapeutic uses
KR20080094064A (ko) 2006-01-17 2008-10-22 바이오렉스 쎄라퓨틱스, 인코포레이티드 식물에서 ｎ-글리칸의 인간화 및 최적화 조성물 및 방법
AU2007226856A1 (en) 2006-03-21 2007-09-27 Michael Rynkiewicz Methods for humanizing antibodies and humanized antibodies made thereby
US7615220B2 (en) 2006-04-07 2009-11-10 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-18 receptor
CN103435697A (zh) 2006-05-15 2013-12-11 航道生物技术有限责任公司 流感病毒的中和抗体
AU2007293662B2 (en) 2006-09-07 2012-10-04 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
CA2664343C (en) 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
CA2668800A1 (en) 2006-11-08 2008-06-05 Macrogenics West, Inc. Tes7 and antibodies that bind thereto
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US8124092B2 (en) 2007-03-13 2012-02-28 Institute For Research In Biomedicine Antibodies against H5N1 strains of influenza A virus
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
KR101732056B1 (ko) 2008-07-25 2017-05-02 인스티튜트 포 리서치 인 바이오메드슨 중화 항-인플루엔자 ａ 바이러스 항체 및 이의 용도
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
EP2328928A2 (en) 2008-08-25 2011-06-08 Dana-Farber Cancer Institute, Inc. Conserved influenza hemagglutinin epitope and antibodies thereto
JP2012508017A (ja) 2008-11-07 2012-04-05 ファブラス エルエルシー 抗ｄｌｌ４抗体及びその使用
US9512182B2 (en) 2010-12-13 2016-12-06 University Of Utah Research Foundation Vaccine antigens that direct immunity to conserved epitopes
CN103906763B (zh) * 2011-07-14 2016-10-12 克鲁塞尔荷兰公司 能够中和系统发育群1和系统发育群2的a型流感病毒以及b型流感病毒的人结合分子
US9587010B2 (en) 2011-07-18 2017-03-07 The Institute For Research In Biomedicine Neutralizing anti-influenza A virus antibodies and uses thereof
EA201490659A1 (ru) 2011-09-20 2014-11-28 Маунт Синай Скул Оф Медсин Вакцины против вируса гриппа и их применения
WO2013044203A2 (en) 2011-09-23 2013-03-28 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPTARTMENT OF HEALTH & HUMAN SERVICES Novel influenza hemagglutinin protein-based vaccines
DK2793945T3 (en) * 2011-12-05 2018-09-03 Trellis Bioscience Llc USEFUL ANTIBODIES FOR PASSIVE INFLUENZA IMMUNIZATION
MY170407A (en) * 2012-03-08 2019-07-27 Crucell Holland Bv Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
EP2919813B1 (en) 2012-11-13 2018-10-24 F.Hoffmann-La Roche Ag Anti-hemagglutinin antibodies and methods of use
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
RU2536956C1 (ru) * 2013-08-05 2014-12-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт пульмонологии Федерального медико-биологического агентства" Противовирусное однодоменное мини-антитело, нуклеотидная последовательность, экспрессирующий рекомбинантный вирусный вектор, фармацевтическая композиция и способ профилактики или терапии гриппа типа а
RU2683498C2 (ru) * 2013-10-02 2019-03-28 МЕДИММЬЮН, ЭлЭлСи Нейтрализующие антитела к вирусу гриппа а и пути их применения
RU2739952C2 (ru) 2014-07-15 2020-12-30 МЕДИММЬЮН, ЭлЭлСи Нейтрализующие антитела к вирусу гриппа b и пути их применения
SI3303384T1 (sl) * 2015-06-01 2021-11-30 Medimmune Llc Nevtralizirajoče vezavne molekule proti-influenci in njihova uporaba
EP3402513A4 (en) 2016-01-13 2019-10-23 Medlmmune, LLC METHOD OF TREATING A FLU
EP3419663A1 (en) 2016-02-24 2019-01-02 Visterra, Inc. Formulations of antibody molecules to influenza virus

Also Published As

Publication number Publication date
HK1250725A1 (zh) 2019-01-11
HK1253092A1 (zh) 2019-06-06
EP3303384A1 (en) 2018-04-11
JP2021112193A (ja) 2021-08-05
BR112017025496A2 (pt) 2018-08-07
CA2987816A1 (en) 2016-12-08
WO2016196470A1 (en) 2016-12-08
JP6867306B2 (ja) 2021-04-28
US11926657B2 (en) 2024-03-12
US11524993B2 (en) 2022-12-13
JP2023078352A (ja) 2023-06-06
AU2016271323A1 (en) 2018-01-18
RU2017145094A3 (el) 2019-11-06
US10882897B2 (en) 2021-01-05
CN107667114B (zh) 2021-07-02
AU2022271473A1 (en) 2022-12-22
US20200109187A1 (en) 2020-04-09
DK3303384T3 (da) 2021-10-18
CN107667114A (zh) 2018-02-06
SI3303384T1 (sl) 2021-11-30
MX2017015189A (es) 2018-04-13
US20210079069A1 (en) 2021-03-18
RU2721706C2 (ru) 2020-05-21
RU2017145094A (ru) 2019-07-09
MX2022001220A (es) 2022-03-02
CN113480640A (zh) 2021-10-08
HRP20211510T1 (hr) 2021-12-24
US10442854B2 (en) 2019-10-15
ES2894777T3 (es) 2022-02-15
AU2016271323B2 (en) 2022-08-25
CA2987816C (en) 2024-02-20
LT3303384T (lt) 2021-10-11
US20180155413A1 (en) 2018-06-07
HUE056407T2 (hu) 2022-02-28
US20230112916A1 (en) 2023-04-13
EP3303384B1 (en) 2021-08-25
PT3303384T (pt) 2021-10-14
RS62446B1 (sr) 2021-11-30
PL3303384T3 (pl) 2022-01-03
EP3960761A1 (en) 2022-03-02
JP2018518475A (ja) 2018-07-12

Similar Documents

Publication Publication Date Title
CY1125793T1 (el) Εξουδετερωτικα μορια δεσμευσης κατα της γριπης και χρησεις αυτων
CY1122653T1 (el) Αντισωματα αντι-τιgιτ, αντισωματα αντι-ρvrig και συνδυασμοι εξ αυτων
CY1125440T1 (el) Αντι-τιμ-3 αντισωματα και συνθεσεις
CY1121197T1 (el) Il2rbhta/koinhς γαμμα αλυσου αντισωματα
CY1124619T1 (el) Αντισωματα αντι-προ/λανθανουσας μυοστατινης και χρησεις αυτων
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
BR112018002432A2 (pt) anticorpos de ligação à il-8 e usos dos mesmos
CL2018002502A1 (es) Conjugados de amanitina.
DK3476399T3 (da) Lag-3-antistof, antigenbindende fragment deraf og farmaceutisk anvendelse deraf
ECSP18000844A (es) Anticuerpos de unión a tau
DK3400293T3 (da) Modificeret onkolytisk virus
DK3265575T3 (da) Cd20-bindende molekyler og anvendelser deraf
BR112017010137A2 (pt) polipeptídios fixadores de pd-l1 para imagem
ECSP18000887A (es) Anticuerpos de unión a tau
CL2015002742A1 (es) Moléculas de unión para bcma y cd3.
DK3374392T3 (da) Forbedrede serumalbuminbindende variable immunglobulindomæner
BR112018010360A2 (pt) fragmentos fab de fator de complemento anti-c1q e utilizações dos mesmos
DK3433280T3 (da) Protease-aktiverede T-celle-bispecifikke molekyler
MA50404A (fr) Protéines immunomodulatrices à variants de ligand de icos variant, compositions et méthodes associées
IT201700095549A1 (it) Piano cottura
DK3242685T3 (da) Cxcr4-bindende molekyler
MA45491A (fr) Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
DK3684416T3 (da) Psma-målrettede amanitinkonjugater
CY1121171T1 (el) Πυρογλουταμικη βορτιοξετινη
CY1120997T1 (el) Πρωτεϊνες συντηξης uti